SCHEMBL5396559

SCHEMBL5396559

Cc1noc(C)c1S(=O)(=O)c1ncn(C(=O)N(C)C)n1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
GAA P10253 2/20 0.38
POLB P06746 2/20 0.36
TSHR P16473 6/20 0.36
DPP4 P27487 1/20 0.35
MAPT P10636 1/20 0.35
NAMPT P43490 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 2/20 0.34
HTT P42858 2/20 0.33
HPGD P15428 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9015559 0.88 ALDH1A1 (0.39) ALDH1A1GAAPOLBTSHRDPP4
SCHEMBL5376972 0.78 ALDH1A1 (0.45) ALDH1A1DPP4MAPTKMT2ANPSR1
SCHEMBL5380508 0.74 POLB (0.55) ALDH1A1POLBTSHRMAPTKMT2A
SCHEMBL5384803 0.74 KMT2A (0.44) ALDH1A1GAADPP4MAPTKMT2A
SCHEMBL5380486 0.72 DPP4 (0.42) DPP4
SCHEMBL5376215 0.72 BRD4 (0.32)
SCHEMBL5384749 0.69 DPP4 (0.40) DPP4
SCHEMBL5385244 0.68 DPP4 (0.48) ALDH1A1DPP4MAPTKMT2ANPSR1
SCHEMBL5376770 0.68 L3MBTL1 (0.34) ALDH1A1TSHRDPP4MAPTKMT2A
SCHEMBL5384837 0.68 KMT2A (0.41) ALDH1A1GAAKMT2ANPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2004-09-23 US disclosed
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI CO., LTD. (JP) 2003-03-27 US disclosed
EP-1258480-A1 Pharmaceutical use of N-Carbamoylazole derivatives Eisai Co., Ltd. (JP) 2002-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 ALDH1A1 1026/4885GAA 215/4885POLB 4436/4885
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 ALDH1A1 1026/4885GAA 215/4885POLB 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.